
Opinion|Videos|September 27, 2024
Frontline Treatment and Sequencing Therapy
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What does your institution use for frontline treatment and how do you sequence therapy for patients who are transplant-eligible?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
2
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
3
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
4
Bridging Response Emerges as Key Predictor of Cilta-Cel Outcomes in CARTITUDE-4
5

















































































































































































































